ENZA-P Big news Update: LuPSMA and enza improves overall survival
A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!! A 45% reduction in the risk of death in favour of the combination. Plus excellent quality of life for those receiving the ...